A somatostatin analogue, octreotide, inhibits the occurrence of second primary tumors and lung metastasis after resection of hepatocellular carcinoma in mice

Tohoku Journal of Experimental Medicine

Volumn 218, Issue 2, 2009, Pages 155-160

  Jia, Wei Dong ^a   Xu, Ge Liang ^a   Wang, Wei ^a   Wang, Zhi Hua ^a   Li, Jian Sheng ^a   Ma, Jin Liang ^a   Ren, Wei Hua ^a   Ge, Yong Sheng ^a   Yu, Ji Hai ^a   Liu, Wen Bin ^a  

^a ANHUI MEDICAL UNIVERSITY   (China)

Author keywords

Angiogenesis; Hepatocellular carcinoma; Metastasis; Octreotide; Vascular endothelial growth factor

Indexed keywords

ALPHA FETOPROTEIN; OCTREOTIDE; VASCULOTROPIN; DRUG DERIVATIVE; SOMATOSTATIN; SOMATOSTATIN RECEPTOR; VASCULOTROPIN A;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER ADJUVANT THERAPY; CANCER INHIBITION; CANCER PREVENTION; CANCER SURGERY; CANCER SURVIVAL; CONTROLLED STUDY; DOWN REGULATION; DRUG EXPOSURE; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; LONGEVITY; LUNG METASTASIS; MALE; METASTASIS POTENTIAL; MICROVASCULATURE; MOUSE; NONHUMAN; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; SECOND CANCER; TREATMENT DURATION; TUMOR XENOGRAFT; ANIMAL; BLOOD; DRUG EFFECT; IMMUNOHISTOCHEMISTRY; LUNG TUMOR; METABOLISM; METASTASIS; PATHOLOGY; VASCULARIZATION; WESTERN BLOTTING;

ANIMALS; BLOTTING, WESTERN; CARCINOMA, HEPATOCELLULAR; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MALE; MICE; MICROVESSELS; NEOPLASMS, SECOND PRIMARY; OCTREOTIDE; RECEPTORS, SOMATOSTATIN; SOMATOSTATIN; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 68549135400     PISSN: 00408727     EISSN: 13493329     Source Type: Journal    
DOI: 10.1620/tjem.218.155     Document Type: Article

References (30)

1. Abou-Alfa, G.K., Huitzil-Melendez, F.D., O'Reilly, E.M. & Saltz, L.B. (2008) Current management of advanced hepatocellular carcinoma. Gastrointest. Cancer Res., 2, 64-70.
2. Cascinu, S., Del Ferro, E., Ligi, M., Staccioli, M.P., Giordani, P., Catalano, V., Agostinelli, R., Muretto, P. & Catalano, G. (2001) Inhibition of vascular endothelial growth factor by octreotide in colorectal cancer patients. Cancer Invest., 19, 8-12.
3. Dasgupta, P. (2004) Somatostatin analogues: multiple roles in cellular proliferation, neoplasia, and angiogenesis. Pharmacol. Ther., 102, 61-85.
4. Dimitroulopoulos, D., Xinopoulos, D., Tsamakidis, K., Zisimopoulos, A., Andriotis, E., Panagiotakos, D., Fotopoulou, A., Chrysohoou, C., Bazinis, A., Daskalopoulou, D. & Paraskevas, E. (2007) Long acting octreotide in the treatment of advanced hepatocellular cancer and overexpression of somatostatin receptors: randomized placebo-controlled trial. World J. Gastroenterol., 13, 3164-3170.
5. Folkman, J. (2002) Role of angiogenesis in tumor growth and metastasis. Semin. Oncol., 29, 15-18.
6. Gill, M.L., Atiq, M., Sattar, S. & Khokhar, N. (2005) Treatment outcomes with long acting octreotide in inoperable hepatocellular carcinoma: a local experience and review of literature. J. Pak. Med. Assoc., 55, 135-138.
7. Huo, T.I., Huang, Y.H., Lui, W.Y., Wu, J.C., Lee, P.C., Chang, F.Y. & Lee, S.D. (2004) Selective prognostic impact of serum alpha-fetoprotein level in patients with hepatocellular carcinoma: analysis of 543 patients in a single center. Oncol. Rep., 11, 543-550.
8. Jia, W.D., Xu, G.L., Xu, R.N., Sun, H.C., Wang, L., Yu, J.H., Wang, J., Li, J.S., Zhai, Z.M. & Xue, Q. (2003) Octreotide acts as an antitumor angiogenesis compound and suppresses tumor growth in nude mice bearing human hepatocellular carcinoma xenografts. J. Cancer Res. Clin. Oncol., 129, 327-334.
9. Kane, R.C., Farrell, A.T., Madabushi, R., Booth, B., Chattopadhyay, S., Sridhara, R., Justice, R. & Pazdur, R. (2009) Sorafenib for the treatment of unresectable hepatocellular carcinoma. Oncologist, 14, 95-100.
10. Kerbel, R.S. (2008) Tumor angiogenesis. N. Engl. J. Med., 358, 2039-2049.
11. Koizumi, M., Onda, M., Tanaka, N., Seya, T., Yamada, T. & Takahashi, Y. (2002) Antiangiogenic effect of octreotide inhibits the growth of human rectal neuroendocrine carcinoma. Digestion, 65, 200-206.
12. Kouroumalis, E., Skordilis, P., Thermos, K., Vasilaki, A., Moschandrea, J. & Manousos, O.N. (1998) Treatment of hepatocellular carcinoma with octreotide: a randomised controlled study. Gut, 42, 442-447.
13. Liao, Y., Tang, Z.Y., Ye, S.L., Liu, K.D., Sun, F.X. & Huang, Z. (2000) Modulation of apoptosis, tumorigenesity and metastatic potential with antisense H-ras oligodeoxynucleotides in a high metastatic tumor model of hepatoma: LCI-D20. Hepatogastroenterology, 47, 365-370.
14. Llovet, J.M., Burroughs, A. & Bruix, J. (2003) Hepatocellular carcinoma. Lancet, 362, 1907-1917.
15. Mazzanti, R., Messerini, L., Comin, C.E., Fedeli, L., Ganne-Carrie, N. & Beaugrand, M. (2007) Liver angiogenesis as a risk factor for hepatocellular carcinoma development in hepatitis C virus cirrhotic patients. World J. Gastroenterol., 13, 5009-5014.
16. Mentlein, R., Eichler, O., Forstreuter, F. & Held-Feindt, J. (2001) Somatostatin inhibits the production of vascular endothelial growth factor in human glioma cells. Int. J. Cancer, 92, 545-550.
17. Muto, Y., Moriwaki, H., Ninomiya, M., Adachi, S., Saito, A., Takasaki, K.T., Tanaka, T., Tsurumi, K., Okuno, M., Tomita, E., Nakamura, T. & Kojima, T. (1996) Prevention of second primary tumors by an acyclic retinoid, polyprenoic acid, in patients with hepatocellular carcinoma. Hepatoma Prevention Study Group. N. Engl. J. Med., 334, 1561-1567.
18. Notas, G., Kolios, G., Mastrodimou, N., Kampa, M., Vasilaki, A., Xidakis, C., Castanas, E., Thermos, K. & Kouroumalis, E. (2004) Cortistatin production by HepG2 human hepatocellular carcinoma cell line and distribution of somatostatin receptors. J. Hepatol., 40, 792-798.
19. Pang, R. & Poon, R.T. (2006) Angiogenesis and antiangiogenic therapy in hepatocellular carcinoma. Cancer Lett., 242, 151-167.
20. Parkin, D.M., Bray, F., Ferlay, J. & Pisani, P. (2005) Global cancer statistics, 2002. CA. Cancer J. Clin., 55, 74-108.
21. Plentz, R.R., Tillmann, H.L., Kubicka, S., Bleck, J.S., Gebel, M., Manns, M.P. & Rudolph, K.L. (2005) Hepatocellular carcinoma and octreotide: treatment results in prospectively assigned patients with advanced tumor and cirrhosis stage. J. Gastroenterol. Hepatol., 20, 1422-1428.
22. Samonakis, D.N., Christodoulakis, N. & Kouroumalis, E.A. (2006) Octreotide for unresectable hepatocellular carcinoma: beyond the first sight. J. Clin. Gastroenterol., 40, 86-87.
23. Sun, H.C., Tang, Z.Y., Li, X.M., Zhou, Y.N., Sun, B.R. & Ma, Z.C. (1999) Microvessel density of hepatocellular carcinoma: its relationship with prognosis. J. Cancer Res. Clin. Oncol., 125, 419-426.
24. Susini, C. & Buscail, L. (2006) Rationale for the use of somatostatin analogs as antitumor agents. Ann. Oncol., 17, 1733-1742.
25. Tung-Ping Poon, R., Fan, S.T. & Wong, J. (2000) Risk factors, prevention, and management of postoperative recurrence after resection of hepatocellular carcinoma. Ann. Surg., 232, 10-24.
26. Vainas, I., Koussis, Ch., Pazaitou-Panayiotou, K., Drimonitis, A., Chrisoulidou, A., Iakovou, I., Boudina, M., Kaprara, A. & Maladaki, A. (2004) Somatostatin receptor expression in vivo and response to somatostatin analog therapy with or without other antineoplastic treatments in advanced medullary thyroid carcinoma. J. Exp. Clin. Cancer Res., 23, 549-559.
27. Wacheck, V., Heere-Ress, E., Halaschek-Wiener, J., Lucas, T., Meyer, H., Eichler, H.G. & Jansen, B. (2001) Bcl-2 antisense oligonucleotides chemosensitize human gastric cancer in a SCID mouse xenotransplantation model. J. Mol. Med., 79, 587-593.
28. Wang, L., Tang, Z.Y., Qin, L.X., Wu, X.F., Sun, H.C., Xue, Q. & Ye, S.L. (2000) High-dose and long-term therapy with interferon-alfa inhibits tumor growth and recurrence in nude mice bearing human hepatocellular carcinoma xenografts with high metastatic potential. Hepatology, 32, 43-48.
29. Weidner, N., Semple, J.P., Welch, W.R. & Folkman, J. (1991) Tumor angiogenesis and metastasis - correlation in invasive breast carcinoma. N. Engl. J. Med., 324, 1-8.
30. Yang, L.Y., Lu, W.Q., Huang, G.W. & Wang, W. (2006) Correlation between CD105 expression and postoperative recurrence and metastasis of hepatocellular carcinoma. BMC. Cancer, 6, 110.